The National Health Surveillance Agency (Anvisa) determined the prohibition of commercialization and advertising of cannabis-based products from two companies. The measure, formalized this Friday (10), directly affects Hemp Vegan and Cannafy Serviços de Internet Ltda.

According to Anvisa, the decision was motivated by the finding that the products were being sold without the proper registration or authorization, violating current sanitary legislation.

Details of Anvisa's prohibition

In the case of Hempvegan, Anvisa vetoed the entire product line, which included drops, gummies, and patches with cannabinoids. The agency's inspection identified that the irregular sale was being carried out directly through the company's website.

In a statement, "Hemp Vegan Brasil LTDA reinforces that it operates in total compliance with ANVISA's norms and RDCs" and strictly follows the legislation for cosmetics and natural products.

The company also clarified that its European operation (hempvegan.health) is distinct from the Brazilian one (hempvegan.com.br), and that the association between the two has led to misunderstandings in Anvisa's records.

What is Cannafy's situation according to Anvisa?

For Cannafy Serviços de Internet Ltda, the measure extends to all cannabis products advertised on its platform. According to Anvisa, the company does not have an Operating Authorization (AFE) to commercialize or manufacture these items in the country.

Cannafy, in turn, argues that it complies with the legislation. The company states that it "does not manufacture or commercialize cannabis products in Brazil," acting only as a facilitator of contact between patients and foreign suppliers for authorized importation.

Anvisa's resolution is broad and affects any individual or communication channel that promotes the products of the mentioned brands.

Not the first time

This is not the first time Hempvegan has been fined by the regulatory agency. In June, Anvisa had already prohibited four cosmetics from the brand that used the term "hemp" in their labels. The four products changed labels and returned to the market.

At the time, the justification was that the word suggested the presence of Cannabis sativa derivatives in the composition, which violates the regulations. The company considered the interpretation "incorrect and lacking technical basis," arguing that the term itself did not indicate the presence of the substance.

Official Statement – Hemp Vegan Brasil LTDA

Hemp Vegan Brasil LTDA reinforces that it operates in total compliance with ANVISA's norms and RDCs related to the cannabis and phytotherapeutic market, in addition to strictly following all current legislation for cosmetics and natural products

We have never manufactured, commercialized, or imported cannabidiol products in Brazil. Our activity is exclusive to the development of natural cosmetics with registration, vegan formulations, and integrative solutions with legal assets in the national territory, always prioritizing the safety, quality, and well-being of our customers.

It is important to clarify that the European operation, hempvegan.health, is distinct from the Brazilian operation, hempvegan.com.br. The company listed in the products registered for importation via RDC 660 is Hemp Vegan Health. The confusion in the association between the companies has been recurrent since March 2025 in Anvisa's records, leading to incorrect interpretations about the advertising of products with cannabidiol.

We have a pipeline of four products under development with phytocannabinoids, currently under analysis for future registration in the country, in partnership with a Brazilian laboratory and pharmaceutical industry.

We reaffirm that all publications and information about cannabidiol products on our website, hempvegan.com.br, are strictly institutional and educational, never constituting direct commercialization, advertising, or offering of unregistered or unauthorized products.

The point that generates the most confusion occurs when there are precedents, as in 2022, as noted in Vote No. 192/2023/SEI/DIRE5/ANVISA (Process SEI No. 25351.910342/2022-02), referring to another company in the sector. This ruling clearly guides on the prohibition of advertising unregulated products and the need for the information conveyed not to constitute drug advertising, in strict compliance with Law No. 6.360/1976. We acted promptly to ensure that the information presentation about cannabidiol on our website strictly followed the interpretations established by Anvisa in this precedent, as per the link.

We are committed to the best practices in research, development, and service in the health sector, maintaining total transparency with regulatory bodies, and are available for any clarifications, reinforcing our commitment to safety, trust, and innovation for Brazilian consumers.

Hemp Vegan Brasil LTDA
Gustavo Sanchez-Palência
CoCEO

Official Statement – Cannafy Serviços de Internet Ltda.

Cannafy clarifies to the public that it rigorously complies with all Brazilian legislation applicable to cannabis products, including Anvisa's RDCs.

We do not manufacture or commercialize cannabis products in Brazil. We only facilitate contact between Brazilian patients and foreign suppliers, ensuring that all imports have been previously authorized by Anvisa, as provided in Anvisa Resolution RDC No. 660/2022.

Our website and materials contain all the warnings required by Anvisa, written in Portuguese, clearly and accessibly, indicating that:

- the acquisition of cannabis-derived products depends on a valid medical prescription;

- the sale and shipment of products are carried out directly by international suppliers, only after proper import authorization by Anvisa.

We reaffirm our commitment to transparency, regulatory compliance, and the safety of Brazilian patients, maintaining ongoing dialogue with sector authorities and partners.